PROMEDIUS Defines Market as Opportunistic Screening of Existing Medical Images
PROMEDIUS identifies its market as opportunistic screening, surfacing aging-related risk signals from imaging data already captured for other purposes.
PROMEDIUS defines its market not as bone densitometry, but as "opportunistic screening," aiming to identify health risks from imaging data already acquired for different reasons. This strategy was detailed by Journey Jin, Head of CEO Office & Board of Directors, in an interview with CB Insights.
The company's approach focuses on leveraging existing medical images to detect signs of aging-related risks. This method avoids the need for patients to undergo additional, dedicated scans for risk assessment.
According to Jin, the precise definition of the market is critical and drives all other strategic decisions within PROMEDIUS. The company seeks to provide valuable health insights by re-examining data that has already been collected.
This strategic focus on opportunistic screening positions PROMEDIUS to offer a unique service in the healthcare technology sector. The company aims to enhance proactive health management by uncovering potential risks embedded within routine imaging.
Further details on PROMEDIUS's technology and its market penetration are expected as the company continues its development and deployment.